The 10,800 FU Nattokinase Study: What Researchers Found in 1,062 Participants

Why does 10,800 FU keep appearing in conversations about nattokinase?

There is a reason.

In 2022, Chen and colleagues reported a retrospective investigation involving 1,062 participants followed for 12 months.

What researchers reported

10,800 FU nattokinase study dose outcome chart

Participants receiving 10,800 FU/day showed significant changes across the reported lipid and carotid measurements after 12 months.

A comparison group receiving 3,600 FU/day did not show comparable significant changes in those reported measurements.

Put simply:

Dose mattered in the Chen study.

The two activity levels did not produce the same reported findings.

What that means — and what it doesn't

PB NATTO Third Party Tested

What PBE learned

For PBE, the important lesson is bigger than the number itself.

The study reinforces the importance of asking:

How much measured activity are we actually delivering?

That question became part of a larger product-development framework:

Nattokinase product development framework graphic

Takeaway

10,800 FU matters because it has a specific human-research history — not because every product carrying a similar number becomes equivalent to the study.

PB Natto

PBE took the activity question further by combining a high-activity, single-capsule formulation with acid-resistant delivery and planned finished-product activity verification.

Explore The Science Behind Nattokinase